The FDA proposed sweeping changes to physician labeling for prescription drugs and biologic products to provide more accurate information about using the agents during pregnancy and breastfeeding.
The Food and Drug Administration (FDA) recently proposed sweeping changes to physician labeling for prescription drugs and biologic products to provide more accurate information to both health-care professionals and their patients about using the agents during pregnancy and breastfeeding.
The hope is that by changing physician labeling, the information will trickle down to women either through package inserts and medication guides or directly through conversation.
The proposed rule would remove the letter category system now in use and replace it with a new pregnancy section on the label that would have three subsections. The first, called the "Fetal Risk Summary," would describe what is known about the effects of the drug on the fetus, including whether the information comes from human or animal studies. The second section called "Clinical Considerations" would include available information about the effects of the agent if it is used before a woman knows she is pregnant. And the third section called "Data" would describe in greater detail studies used to provide information for the "Fetal Risk Summary" section.
FDA proposes new rule to provide updated information on the use of prescription drugs and biological products during pregnancy and breast-feeding. Http:// http://www.fda.gov/bbs/topics/NEWS/2008/NEW01841.html. Accessed 5/28/08.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More